Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Rev Neurol ; 63(9): 411-414, 2016 Nov 01.
Article in Spanish, English | MEDLINE | ID: mdl-27779301

ABSTRACT

INTRODUCTION: Congenital glioblastoma multiforme represents only 3% of congenital central nervous system tumours and an infratentorial location is unusual. CASE REPORT: A newborn with congenital glioblastoma multiforme with no mutation in the TP53 gene or p53 nuclear immunoreactivity that infiltrated practically the whole brainstem and also invaded supratentorial structures. CONCLUSIONS: As far as we know, only four cases with an infratentorial location have been reported previously, three in the cerebellum and one in the brainstem. The biology of congenital glioblastoma multiforme is not well known and, unlike glioblastoma multiforme in adults and children, mutations in the TP53 gene are uncommon. However, this is not associated with a more favourable prognosis. These observations suggest that specific biological processes underlie fetal glioblastoma multiforme development.


TITLE: Glioblastoma multiforme congenito infratentorial. Un tumor excepcional con una biologia aun desconocida.Introduccion. El glioblastoma multiforme congenito representa solo el 3% de los tumores congenitos del sistema nervioso central, y su ubicacion infrantentorial es excepcional. Caso clinico. Recien nacido con un glioblastoma multiforme congenito sin mutacion en el gen TP53 ni inmunorreactividad nuclear p53, que infiltraba practicamente todo el tronco cerebral e invadia tambien estructuras supratentoriales. Conclusiones. Hasta donde sabemos, solo se han referido previamente cuatro casos de localizacion infratentorial, tres en el cerebelo y uno en el tronco del encefalo. La biologia del glioblastoma multiforme congenito no se conoce bien y, a diferencia del glioblastoma multiforme en la edad adulta, las mutaciones en el gen TP53 son poco frecuentes, sin que eso parezca implicar un mejor pronostico. Estas observaciones sugieren que el glioblastoma multiforme con origen en la vida fetal tiene una biologia diferente del que se presenta en otras etapas de la vida.


Subject(s)
Glioblastoma/congenital , Infratentorial Neoplasms/congenital , Brain Stem/pathology , Humans , Infant, Newborn , Mutation
6.
An. pediatr. (2003, Ed. impr.) ; 77(2): 88-97, ago. 2012. tab, graf
Article in Spanish | IBECS | ID: ibc-102749

ABSTRACT

Introducción: La hipotermia cerebral moderada ha probado ser una intervención eficaz para reducir la mortalidad y la discapacidad mayor en los neonatos con encefalopatía hipóxico-isquémica (EHI) moderada-grave. Objetivos: Describir la experiencia en el primer año de su utilización y valorar la factibilidad y seguridad de esta intervención. Métodos: Revisión de los 20 pacientes con EHI moderada-grave tratados con hipotermia corporal total en la Agrupación Sanitaria Hospital Sant Joan de Déu-Hospital Clínic, entre enero de 2009 y junio de 2010. Resultados: Durante este periodo ingresaron 50 neonatos con EHI perinatal, en 26 de ellos moderada-grave. Un total de 20 neonatos recibieron hipotermia (13 con EHI grave y 7 moderada). En todos ellos se encontró un antecedente de riesgo de hipoxia-isquemia perinatal y algún signo clínico de EHI. Quince neonatos presentaron convulsiones clínicas y/o en el registro electroencefalográfico. La temperatura rectal se mantuvo en 33,5±0,5°C en el 76,5% de las determinaciones para los neonatos con control manual de la temperatura y en el 93,6% para los manejados con servocontrol (p<0,0001). El recalentamiento se realizó en una mediana de 10,5 horas. No se produjo ninguna complicación potencialmente grave relacionada con la hipotermia. Fallecieron 7 neonatos (35%), todos ellos con EHI grave. Conclusiones: No se han apreciado dificultades en ninguna de las fases de esta intervención terapéutica ni se ha registrado ninguna complicación potencialmente grave relacionada con ella. Tanto el control manual de la temperatura como su servocontrol son eficaces para mantener la temperatura diana, pero esta muestra una menor variabilidad con el equipo servocontrolado(AU)


Introduction: Moderate cerebral hypothermia has been shown to be an effective intervention in decreasing mortality and major disabilities in infants with moderate-severe hypoxic-ischaemic encephalopathy (HIE). Objectives: To describe our experience within the first year of implementation, and to evaluate the feasibility and safety of this intervention. Methods: Retrospective study of 20 patients with moderate-severe HIE treated with whole body hypothermia in the Agrupación Sanitaria Hospital Sant Joan de Déu-Hospital Clínic, between January 2009 and June 2010.ResultsDuring this period, 50 patients with perinatal HIE, 26 of them moderate- severe, were admitted to our units. Twenty patients received hypothermia (13 with severe and 7 with moderate HIE). All of them had at least one risk factor for perinatal hypoxia-ischaemia, and clinical signs of HIE. Fifteen had clinical and/or EEG seizures. Core temperature was maintained at 33.5±0.5°C in 76.5% of determinations for infants cooled with a manual control device, and in 93.6% for those cooled with a servo-controlled device (P<0,0001). Re-warming took a median time of 10.5hours. No potentially severe complications related to hypothermia were observed. Seven patients (35%) died, all of them with severe HIE. Conclusions: There were no difficulties in any of the steps of this intervention, and no potentially severe complications related to it were recorded. Both manual and servo-control methods are equally effective on maintaining the target temperature, although temperature shows less variability using the servo-controlled equipment(AU)


Subject(s)
Humans , Male , Female , Infant, Newborn , Hypothermia/complications , Hypothermia/diagnosis , Hypoxia-Ischemia, Brain/complications , Hypoxia-Ischemia, Brain/diagnosis , Electroencephalography , Clinical Protocols/standards , Neuroimaging/methods , Neuroimaging , Hypothermia/physiopathology , Hypothermia , Hypoxia, Brain/complications , Brain Ischemia/complications , Hypoxia-Ischemia, Brain/physiopathology , Hypoxia-Ischemia, Brain , Retrospective Studies , Cohort Studies , Data Collection/methods , Data Collection
7.
An Pediatr (Barc) ; 77(2): 88-97, 2012 Aug.
Article in Spanish | MEDLINE | ID: mdl-22406158

ABSTRACT

INTRODUCTION: Moderate cerebral hypothermia has been shown to be an effective intervention in decreasing mortality and major disabilities in infants with moderate-severe hypoxic-ischaemic encephalopathy (HIE). OBJECTIVES: To describe our experience within the first year of implementation, and to evaluate the feasibility and safety of this intervention. METHODS: Retrospective study of 20 patients with moderate-severe HIE treated with whole body hypothermia in the Agrupación Sanitaria Hospital Sant Joan de Déu-Hospital Clínic, between January 2009 and June 2010. RESULTS: During this period, 50 patients with perinatal HIE, 26 of them moderate- severe, were admitted to our units. Twenty patients received hypothermia (13 with severe and 7 with moderate HIE). All of them had at least one risk factor for perinatal hypoxia-ischaemia, and clinical signs of HIE. Fifteen had clinical and/or EEG seizures. Core temperature was maintained at 33.5 ± 0.5°C in 76.5% of determinations for infants cooled with a manual control device, and in 93.6% for those cooled with a servo-controlled device (P<.0001). Re-warming took a median time of 10.5 hours. No potentially severe complications related to hypothermia were observed. Seven patients (35%) died, all of them with severe HIE. CONCLUSIONS: There were no difficulties in any of the steps of this intervention, and no potentially severe complications related to it were recorded. Both manual and servo-control methods are equally effective on maintaining the target temperature, although temperature shows less variability using the servo-controlled equipment.


Subject(s)
Hypothermia, Induced/methods , Hypoxia-Ischemia, Brain/therapy , Feasibility Studies , Female , Humans , Infant, Newborn , Male , Retrospective Studies , Time Factors
8.
An. pediatr. (2003, Ed. impr.) ; 74(5): 309-316, mayo 2011. tab, graf
Article in Spanish | IBECS | ID: ibc-90328

ABSTRACT

Introducción: El aumento en la supervivencia de recién nacidos de muy bajo peso (RNMBP) y su morbilidad neuroevolutiva obliga a implementar programas de seguimiento, cuyo abandono limita la consecución de los objetivos asistenciales y la validez de los estudios. Objetivos: De los RNMBP asistidos entre 2002-2005 en nuestra unidad neonatal y perdidos en seguimiento antes de 2 años, se pretende conocer su neurodesarrollo, morbilidad post-alta y situación sociocultural y compararlos con los seguidos. Pacientes: Se asiste a 318 RNMBP, de los cuales 53 (16,6%) fallecen. A los 2 años completan el seguimiento 215 (grupo S) y 50 lo abandonan (grupo A).Métodos: Revisión de historias y bases de datos. Entrevista telefónica sistematizada a padres que abandonan seguimiento. Resultados: Se entrevista a 30 casos (grupo R) del grupo perdido. De ellos, 6 pacientes ingresan por patología respiratoria; el 26,7% (8 casos) presenta secuelas neuroevolutivas (1 grave; 1moderada; 6 leves) frente al 14% en el grupo S (p < 0,05). El grupo R, comparado con el grupo S, presenta una mayor tasa de inmigración (14 vs 40%), menor nivel de estudios parental y mayor distancia casa-hospital (p < 0,05). En el grupo R, el 57% tiene nivel socioeconómico bajo. Conclusiones: La entrevista telefónica ha permitido conocer la situación clínica del 60% de RNMBP perdidos en seguimiento. Hay una mayor tasa de secuelas en el grupo perdido, aunque en su mayoría son leves. Una serie de factores sociales, económicos y culturales desfavorableshan podido influir en el abandono. Conviene elaborar estrategias para evitar en lo posible pérdidas en el seguimiento (AU)


Introduction: The increase in survival rates of very low weight newborns (VLWN) and their neurodevelopmental morbidity has led to the implementation of follow-up programmes. The withdrawal from follow up limits the achievement of care goals and the validity of studies in this field. Goals: To assess the neurodevelopmental status, morbidity, social and economical data in the VLWN seen in our Neonatal Care Unit between 2002 and 2005 and lost in the follow up programme before the age of two, and compare these findings with the group who completed follow up. Patients: A total of 318 VLWN were included, of 53 had died. At the age of two, 215 had completed the monitoring visits (group S) and 50 had quit (group A).Methods: Using the SEN 1500 data base, and telephone interview of those parents who quit the programme. Results: A total of 30 cases were interviewed (Group R). Six patients had e been admitted to hospital due to respiratory illness; 26.7% had neurodevelopmental impairment (1 case, severe;1 case, moderate; 6 cases, mild) compared to 14% in group S (P < 0.05). In group R, compared with group S, included more immigrants (40 vs. 14%), parental education level was lower and distance between home and hospital was greater (P < 0.05). In group R, 57% of families had a low socioeconomic standard. Conclusions: The telephone interview allowed the clinical status of 60% of VLWN lost to follow up to be determined. Sequelae rate, mainly mild, was higher in the lost-to follow-up group. Some unfavourable social, economical and cultural factors could have influenced the interruption. It is advisable to develop strategies to prevent loss in the follow up (AU)


Subject(s)
Humans , Male , Female , Infant , Infant, Very Low Birth Weight/growth & development , Infant, Premature, Diseases/epidemiology , Statistics on Sequelae and Disability , Patient Dropouts/statistics & numerical data , Follow-Up Studies , Risk Factors
9.
An Pediatr (Barc) ; 74(5): 309-16, 2011 May.
Article in Spanish | MEDLINE | ID: mdl-21345756

ABSTRACT

INTRODUCTION: The increase in survival rates of very low weight newborns (VLWN) and their neurodevelopmental morbidity has led to the implementation of follow-up programmes. The withdrawal from follow up limits the achievement of care goals and the validity of studies in this field. GOALS: To assess the neurodevelopmental status, morbidity, social and economical data in the VLWN seen in our Neonatal Care Unit between 2002 and 2005 and lost in the follow up programme before the age of two, and compare these findings with the group who completed follow up. PATIENTS: A total of 318 VLWN were included, of 53 had died. At the age of two, 215 had completed the monitoring visits (group S) and 50 had quit (group A). METHODS: Using the SEN 1500 data base, and telephone interview of those parents who quit the programme. RESULTS: A total of 30 cases were interviewed (Group R). Six patients had been admitted to hospital due to respiratory illness; 26.7% had neurodevelopmental impairment (1 case, severe; 1 case, moderate; 6 cases, mild) compared to 14% in group S (P<.05). In group R, compared with group S, included more immigrants (40 vs. 14%), parental education level was lower and distance between home and hospital was greater (P<.05). In group R, 57% of families had a low socioeconomic standard. CONCLUSIONS: The telephone interview allowed the clinical status of 60% of VLWN lost to follow up to be determined. Sequelae rate, mainly mild, was higher in the lost-to- follow-up group. Some unfavourable social, economical and cultural factors could have influenced the interruption. It is advisable to develop strategies to prevent loss in the follow up.


Subject(s)
Child Development , Infant, Very Low Birth Weight , Patient Dropouts/statistics & numerical data , Surveys and Questionnaires , Female , Follow-Up Studies , Humans , Infant, Newborn , Male , Retrospective Studies
10.
Rev. neurol. (Ed. impr.) ; 32(4): 333-335, 16 feb., 2001.
Article in Es | IBECS | ID: ibc-21871

ABSTRACT

Introducción. La linfohistiocitosis hemofagocítica (LHH) es una enfermedad hematológica, autosómica recesiva, en la que se produce una proliferación benigna de histiocitos con intensa actividad fagocítica de células hematopoyéticas. Cursa con fiebre, pancitopenia, trastornos de la coagulación, disfunción hepática, presencia de histiocitos y hemofagocitos en médula ósea, nódulos linfáticos, bazo e hígado. El compromiso del sistema nervioso es constante y todos los pacientes desarrollan más tarde o más temprano un cuadro neurológico que puede manifestarse con síntomas variables como irritabilidad, trastornos de conciencia, convulsiones, ataxia, nistagmo o signos de hipertensión intracraneal. Caso clínico. El debut de la enfermedad con un cuadro exclusivamente neurológico es poco común y por ello presentamos la observación de un lactante de 8 meses con LHH que presenta un cuadro exclusivamente neurológico, en forma de irritabilidad y movimientos oculares rápidos horizontales y sacádicos verticales de ambos ojos y crisis convulsivas focales. Los exámenes complementarios iniciales fueron normales, excepto el estudio del LCR que reveló hiperproteinorraquia y celularidad (monocitos). La evidencia de sustancia blanca con áreas de edema, necrosis y atrofia cortical [1,3,5]. una hepatoesplenomegalia y palidez, junto a la analítica, aconsejó practicar una punción biopsia de médula ósea que detectó hemofagocitos, diagnóstico de LHH. A pesar del tratamiento quimioterápico se produjo un rápido deterioro neurológico, con alteraciones en la sustancia blanca y acompañado de hidrocefalia que requirió derivación ventriculoperitoneal. El paciente falleció a los 10 meses. Conclusión. Los casos de LHH en los que el compromiso cerebromeníngeo exclusivo precede a los síntomas sistémicos es extremadamente raro, de aquí el interés en comunicarlo y tenerlo en cuenta frente a un paciente con una clínica neurológica aguda, en este caso exclusivamente de encefalitis pero que se complicó rápidamente con manifestaciones sistémicas (AU)


Subject(s)
Middle Aged , Male , Infant , Humans , Steroids , Saccades , Splenomegaly , Tomography, X-Ray Computed , Cyclosporine , Histiocytosis, Non-Langerhans-Cell , Encephalitis, Viral , Ventriculoperitoneal Shunt , Fatal Outcome , Methotrexate , Pancytopenia , Nystagmus, Pathologic , Peripheral Nervous System Diseases , Brain Stem , Anti-Inflammatory Agents , Anticonvulsants , Antineoplastic Combined Chemotherapy Protocols , Behcet Syndrome , Diagnosis, Differential , Drug Resistance , Dexamethasone , Hepatomegaly , Magnetic Resonance Imaging , Electroencephalography , Encephalitis , Epilepsies, Partial , Etoposide , Fever , Seizures , Bone Marrow , Hydrocephalus
SELECTION OF CITATIONS
SEARCH DETAIL
...